SEC Form 3 · accession 0001397266-26-000004
Electra Therapeutics, Inc. · ETRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew K Fust
Director
Period of report
Sep 18, 2026
Accepted (ET)
Sep 18, 2026 · 4:23 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0002088082
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Director Stock Option (right to buy)F1 | $4.40 | holding | — | — | — | — | Nov 16, 2033 | Common Stock | 59,086 | — | D |
| Director Stock Option (right to buy)F2 | $4.96 | holding | — | — | — | — | Feb 12, 2036 | Common Stock | 77,714 | — | D |
| Director Stock Option (right to buy)F3 | $15.00 | holding | — | — | — | — | Sep 16, 2036 | Common Stock | 22,632 | — | D |
Explanation of responses
- F11/4th of the total shares subject to this option vested one year after October 16, 2023, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
- F21/48th of the total shares subject to this option shall vest monthly commencing from February 1, 2026. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
- F3The shares subject to this option shall vest on the earlier of September 17, 2027 and the date of the next annual meeting of the Issuer's stockholders.